Retatrutide
Explore peptide research and guides on retatrutide.
How Retatrutide Targets Three Receptors at Once
Retatrutide activates GLP-1, GIP, and glucagon receptors from one peptide. How triple agonism produces 24-28% weight loss and what each receptor does.
RetatrutideRetatrutide and Liver Fat: The MASH Connection
Retatrutide reduced liver fat by 82% in a phase 2a trial, with 93% of participants achieving normal levels at 48 weeks. The triple agonist's MASLD data explained.
RetatrutideRetatrutide Clinical Trials: Up to 24% Weight Loss
Retatrutide clinical trial results: 24.2% weight loss at 48 weeks in phase 2, up to 28.7% in phase 3. Triple agonist data, safety, and body composition.
RetatrutideRetatrutide: The Triple Agonist for Weight Loss
Retatrutide targets GLP-1, GIP, and glucagon receptors for up to 28.7% weight loss. Here's what the phase 2 and phase 3 clinical data shows.
RetatrutideRetatrutide vs Tirzepatide vs Semaglutide
Retatrutide vs tirzepatide vs semaglutide compared: weight loss data, receptor targets, safety, body composition, and liver fat from clinical trials.
RetatrutideWhen Will Retatrutide Be Available?
Retatrutide Phase 3 trials are reporting results in 2026. Here's the realistic FDA approval timeline, what the data shows so far, and when patients might get access.